AGE Overzicht aandelen
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
AgeX Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$11.10 |
| 52 Week Hoogtepunt | US$35.17 |
| 52 Week Laag | US$10.90 |
| Bèta | 1.19 |
| 11 maand verandering | -14.70% |
| 3 maanden verandering | -23.49% |
| 1 Jaar Verandering | -48.68% |
| 33 jaar verandering | -80.64% |
| 5 jaar verandering | -92.39% |
| Verandering sinds IPO | -88.35% |
Recent nieuws en updates
Rendement voor aandeelhouders
| AGE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -23.6% | -0.7% | -1.6% |
| 1Y | -48.7% | 19.8% | 30.8% |
Rendement versus industrie: AGE underperformed the US Biotechs industry which returned 10.2% over the past year.
Rendement versus markt: AGE underperformed the US Market which returned 29.8% over the past year.
Prijsvolatiliteit
| AGE volatility | |
|---|---|
| AGE Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: AGE's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: AGE's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Joanne Hackett | www.agexinc.com |
AgeX Therapeutics, Inc. Samenvatting
| AGE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$31.51m |
| Inkomsten(TTM) | -US$14.80m |
| Inkomsten(TTM) | US$142.00k |
195.5x
P/S-verhouding-1.9x
Koers/WinstverhoudingIs AGE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AGE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$142.00k |
| Kosten van inkomsten | US$40.00k |
| Brutowinst | US$102.00k |
| Overige uitgaven | US$14.91m |
| Inkomsten | -US$14.80m |
Laatst gerapporteerde inkomsten
Dec 31, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -5.92 |
| Brutomarge | 71.83% |
| Nettowinstmarge | -10,424.65% |
| Schuld/Eigen Vermogen Verhouding | 81.5% |
Hoe presteerde AGE op de lange termijn?
Bekijk historische prestaties en vergelijking